LUND UNIVERSITY

The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.

Olsson, Linda; Ivanov Öfverholm, Ingegerd; Norén-Nyström, Ulrika; Zachariadis, Vasilios; Nordlund, Jessica; Sjögren, Helene; Golovleva, Irina; Nordgren, Ann; Paulsson, Kajsa; Heyman, Mats; Barbany, Gisela; Johansson, Bertil

Published in:

British Journal of Haematology

DOI:

[10.1111/bjh.13514](https://doi.org/10.1111/bjh.13514)

2015

[Link to publication](#)

Citation for published version (APA):

Olsson, L., Ivanov Öfverholm, I., Norén-Nyström, U., Zachariadis, V., Nordlund, J., Sjögren, H., Golovleva, I., Nordgren, A., Paulsson, K., Heyman, M., Barbany, G., & Johansson, B. (2015). The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. *British Journal of Haematology*, 170(6), 847-858. <https://doi.org/10.1111/bjh.13514>

Total number of authors:

12

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

The clinical impact of *IKZF1* deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in NOPHO treatment protocols used between 1992 and 2013

Linda Olsson,^{1,9} Ingegerd Ivanov Öfverholm,^{2,9} Ulrika Norén-Nyström,³ Vasilios Zachariadis,² Jessica Nordlund,⁴ Helene Sjögren,⁵ Irina Golovleva,⁶ Ann Nordgren,² Kajsa Paulsson,¹ Mats Heyman,⁷ Gisela Barbany^{2,10} and Bertil Johansson^{1,8,10}

¹*Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden,* ²*Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden,* ³*Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden,* ⁴*Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden,* ⁵*Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,* ⁶*Department of Medical Biosciences, Medical and Clinical Genetics, Umeå University, Umeå, Sweden,* ⁷*Department of Women's and Children's Health, Karolinska Institutet, Stockholm Sweden,* ⁸*Department of Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, Sweden,* ⁹*These first authors contributed equally to this work,* ¹⁰*These senior authors contributed equally to this work*

Correspondence: Linda Olsson, Division of Clinical Genetics, Department of Laboratory Medicine, BMC C13, Lund, SE-221 84, Sweden or Ingegerd Ivanov Öfverholm, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, SE-171 76, Sweden.

E-mail: Linda.olsson@med.lu.se or Ingegerd.ofverholm@ki.se

Running head: *IKZF1* in paediatric BCP ALL

Summary

Paediatric B-cell precursor acute lymphoblastic leukaemias (BCP ALL) with *IKZF1* deletions (Δ IKZF1) are associated with a poor outcome. However, there are conflicting data as to whether Δ IKZF1 is an independent risk factor if MRD and other copy number alterations also are taken into account. We investigated 334 paediatric BCP ALL, diagnosed 1992-2013 and treated according to NOPHO ALL protocols, with known *IKZF1* status based on either SNP array ($N=218$) or MLPA ($N=116$) analyses. Δ IKZF1, found in 15%, was associated with inferior 10-year probabilities of event-free (60% vs. 83%; $P<0.001$) and overall survival (pOS; 73% vs. 89%; $P=0.001$). Adjusting for known risk factors, including WBC count and MRD, Δ IKZF1 was the strongest independent factor for relapse and death. Δ IKZF1 was present in 27% of cases with non-informative cytogenetics (“BCP-other”) and a poor 10-year pOS was particularly pronounced in this group (58% vs. 90%; $P<0.001$). Importantly, neither MRD nor WBC count predicted events in the Δ IKZF1-positive cases. Co-occurrence of pseudoautosomal region 1 (PAR1) deletions in Xp22.33/Yp11.32 (*P2RY8-CRLF2*) and Δ IKZF1 increased the risk of relapse (75% vs. 30% for cases with only Δ IKZF1; $P=0.045$), indicating that BCP-other ALL with both *P2RY8-CRLF2* and Δ IKZF1 constitutes a particular high risk group.

Keywords: Paediatric B-cell precursor acute lymphoblastic leukaemia; *IKZF1* deletion; *P2RY8-CRLF2*, *ERG* deletion, minimal residual disease; risk-stratifying factors.

Deletions of the *IKZF1* gene (Δ IKZF1), encoding the transcription factor IKAROS (Georgopoulos *et al*, 1992), occur in approximately 15% of paediatric B-cell acute lymphoblastic leukaemia (BCP ALL) (Olsson & Johansson, 2015). In recent years, several studies have shown that Δ IKZF1 is significantly associated with decreased event-free survival (EFS) and overall survival (OS) both in the non-high risk (NHR) and high risk (HR) groups. Of particular interest is the fact that Δ IKZF1 confers a poor prognosis in cases with non-specific cytogenetic aberrations, normal karyotypes, or karyotypic failures, *i.e.*, “BCP-other” ALL (Mullighan *et al*, 2009; Kuiper *et al*, 2010; Waanders *et al*, 2011; Dörge *et al*, 2013; Öfverholm *et al*, 2013; van der Veer *et al*, 2013; Olsson *et al*, 2014). However, the clinical impact of Δ IKZF1 may be modified by other genetic aberrations, such as rearrangements of *CRLF2*, *e.g.*, pseudoautosomal region 1 (PAR1) deletions in Xp22.33/Yp11.32 resulting in *P2RY8-CRLF2*, and deletions of the *ERG* gene in 21q22.2, as well as by minimal residual disease (MRD) stratification (Chen *et al*, 2012; Palmi *et al*, 2013; Volejnikova *et al*, 2013; Clappier *et al*, 2014; Zaliouva *et al*, 2014; Olsson *et al*, 2015). Some studies have included MRD data when addressing the prognostic impact of Δ IKZF1 in paediatric BCP ALL, but the results have been conflicting as to whether Δ IKZF1 is an independent risk factor (Mullighan *et al*, 2009; Waanders *et al*, 2011; Dörge *et al*, 2013; van der Veer *et al*, 2013) or not (Chen *et al*, 2012; Volejnikova *et al*, 2013). Considering that several ongoing treatment protocols use MRD findings for risk stratification (Borowitz *et al*, 2008; Brüggemann *et al*, 2010; Yamaji *et al*, 2010; Vora *et al*, 2013; Frandsen *et al*, 2014), it is crucial to analyse the relationship between Δ IKZF1 and MRD findings before implementing analyses of Δ IKZF1 in clinical routine.

The rationale for the present study, which is based on 334 Swedish paediatric BCP ALL cases with known *IKZF1* status diagnosed between 1992 and 2013 and treated according to the NOPHO ALL-1992, -2000, and -2008 protocols (Schmiegelow *et al*, 2010; Frandsen *et al*,

2014), was two-fold: first, to ascertain if $\Delta IKZF1$ is an independent risk factor also in the context of MRD and second, to investigate further the prognostic impact of $\Delta IKZF1$ in different patient/cytogenetic groups and in relation to co-occurring *ERG* and *PAR1* deletions.

Patients and methods

Patient cohort

The *IKZF1* status, *i.e.*, deleted or not deleted, was ascertained in a total of 354 BCP ALL cases diagnosed morphologically, immunophenotypically, and genetically as requested by the NOPHO ALL-1992, -2000, and -2008 protocols (Schmiegelow *et al*, 2010; Frandsen *et al*, 2014). Of these, 13 were infant ALL, none of which harboured $\Delta IKZF1$, and seven were *BCR-ABL1*-positive cases, three of which had $\Delta IKZF1$; these 20 BCP ALLs were excluded from further analysis. The remaining 334 patients were all treated according to the above-mentioned NOPHO protocols. Patients stratified into standard risk/intensity or intermediate risk/intensity groups in the 1992, 2000, and 2008 protocols were in this study grouped together as standard risk (SR; $N=136$) and intermediate risk (IR; $N=140$), respectively. Patients stratified into high- or very high-risk (1992), intensive, very intensive, or extra intensive (2000), or high-risk-chemo or high-risk-SCT (2008) were here combined into HR ($N=58$). The median age was 4.0 years (range 1 – 17 years), the male/female ratio 1.1, and the median white blood cell (WBC) count $9.7 \times 10^9/l$ (range $0.9 - 1161 \times 10^9/l$). The basic clinical features are given in Table SI. The genetic investigations were approved by the Research Ethics Committees at the participating centres and informed consent was obtained according to the Declaration of Helsinki.

MRD analysis

Response to therapy was assessed by MRD analysis at day 29, as previously described (Schmiegelow *et al*, 2010; Toft *et al*, 2013). Of the 334 BCP ALL cases, MRD data were available for 219 (66%) patients, of whom 61 (28%) were MRD positive ($\geq 0.1\%$) and 158 (72%) were MRD negative ($< 0.1\%$). In accordance with the NOPHO ALL 2008 protocol, MRD measurements by flow cytometry were used in most instances ($N=212$; 97%), but for the seven cases where this was not feasible (no aberrant immunophenotypic markers), MRD analyses were performed by polymerase chain reaction (PCR). In the current 2008 protocol, MRD is used as a risk stratifying factor, directly influencing the therapy given (Toft *et al* 2013).

Cytogenetic analyses

Chromosome banding analyses were performed using standard methods in four cytogenetic laboratories in Sweden. All abnormal karyotypes have been centrally reviewed each year since 1996 by the Swedish Childhood Leukaemia Cytogenetics Group. Fluorescence *in situ* hybridisation (FISH) or reverse-transcription PCR analyses were used to screen for the translocations/gene fusions t(1;19)(q23;p13) [*TCF3-PBX1*], t(9;22)(q34;q11) [*BCR-ABL1*], and t(12;21)(p13;q22) [*ETV6-RUNX1*], whereas FISH or Southern blot analyses were used to identify 11q23/*KMT2A* (a.k.a *MLL*) rearrangements. These targeted analyses have been performed prospectively from 1996, with several additional cases prior to this time having been ascertained retrospectively. In the NOPHO ALL-2008 protocol, screening for intrachromosomal amplification of chromosome 21 (iAMP21) and dic(9;20)(p13;q11) became mandatory (Frandsen *et al*, 2014); however, many cases diagnosed before 2008 have been identified in retrospective analyses. The genetic findings are summarized in Table SI.

SNP and MLPA analyses

Of the 334 cases, 218 (65%) had been analysed by single nucleotide polymorphism (SNP) arrays and 116 (35%) by multiplex ligation-dependent probe amplification (MLPA). The *IKZF1* status of 286 cases has been reported previously (Öfverholm *et al*, 2013; Olsson *et al*, 2014). PAR1 deletions were ascertained by SNP array or MLPA analyses in all cases, whereas the *ERG* status could be determined in 246 cases (apart from the 218 cases analysed by SNP arrays, array-CGH data on *ERG* were available in 28 of the 116 cases analysed by MLPA).

The platforms used for SNP array analyses were HumanOmniExpress BeadChip (Illumina, San Diego, CA, USA), Human 610-Quad BeadChip (Illumina), HumanOmni1-Quad BeadChip (Illumina), Human1M-Duo BeadChip (Illumina), or Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). The copy number (CN) state was determined using the GenomeStudio 2011.1 (Illumina), Chromosome Analysis Suite (Affymetrix), or the Nexus Copy Number (BioDiscovery, Hawthorne, CA, USA) software. The criterion to “call” a deletion by SNP arrays was a minimum of three consecutive probes deleted. For cases analysed by the Nexus Copy Number software, the confidence threshold was set to >35. Deletions seen in remission samples or that overlapped with copy number polymorphisms listed in the Database of Genomic Variants (<http://projects.tcag.ca/variation/>) were excluded.

For the MLPA analyses, the probe kits P335 and P202 (MRC-Holland, Amsterdam, The Netherlands) were used. The P335 probe mix contains one probe each for all eight exons of the *IKZF1* gene, seven probes for *PAX5*, six probes for *ETV6*, five probes for *RBI*, four probes for *BTG1* and the *BTG1* downstream region, four probes for *EBF1*, three probes for *CDKN2A/B*, and five probes for the PAR1 region (*SHOX*, *CRLF2*, *CSF2RA*, *IL3RA*, and *P2RY8*). Peaks were normalised against controls to generate relative CN states of the exons in the sample. Relative peak heights between 0.75 and 1.35 were considered normal (CN 2),

whereas values below 0.75 and above 1.35 were considered to represent losses (CN 1) and gains (CN 3), respectively. Values below 0.25 indicated biallelic loss (CN 0). Samples with deletions in *IKZF1* were further analysed with the probe kit P202, which contains two probes per exon of this gene. *IKZF1* deletions that affected single probes in the P335 kit were only regarded as positive if validated by the P202 kit.

Statistical analyses

The PASW Statistics 20 software for Windows (SPSS Inc., Chicago, IL, USA) was applied for all analyses. The significance limit for two-sided *P*-values was set to <0.05. The Mann-Whitney U-test for continuous variables and the two-tailed Fisher's exact probability test for discrete variables were used to compare clinical and genetic features between cases with known *IKZF1* status (the present cohort of 334 cases) and those with unknown *IKZF1* status (*N*=799) as well as between *IKZF1* deleted (*N*=50) and non-deleted cases (*N*=284). In the EFS analysis, events comprised induction failure, relapse, death in first complete remission, and secondary malignant neoplasm. For OS, death was the only event and in estimations of cumulative incidence of relapse (Rel), only relapses were counted. The 10-year (yr) probabilities of relapse (pRel), EFS (pEFS), and OS (pOS) in cases with and without *IKZF1* deletions were calculated using the Kaplan-Meier method. Multivariate analysis using a Cox regression model was performed to ascertain if Δ *IKZF1* had an independent impact on pRel, pEFS, and/or pOS. The median observation time for patients in complete remission 1 (CR1) was 89 months (range 1 – 200 months).

Results

The investigated cohort is representative of paediatric BCP ALL in general

A total of 1133 Swedish children/adolescents (1-17 years) were diagnosed with *BCR-ABL1*-negative BCP ALL and treated in accordance with the NOPHO protocols between 1992 and 2013. Comparing the 334 (29%) cases analysed for $\Delta IKZF1$ presented herein with the 799 (71%) cases with unknown *IKZF1* status revealed no significant differences with regard to age, gender, proportion of patients with Down syndrome, risk stratification, number of patients undergoing allogeneic stem cell transplantation (allo SCT), 10-yr pRel, 10-yr pEFS, 10-yr pOS, and MRD findings at day 29 (Table SII). However, the median WBC count was higher in the investigated cohort: $9.7 \times 10^9/l$ (range $0.9 - 1161 \times 10^9/l$) vs. $7.4 \times 10^9/l$ (range $0.3 - 381 \times 10^9/l$; $P = 0.001$).

Frequencies and types of $\Delta IKZF1$

Fifty (15%) of the 334 cases harboured $\Delta IKZF1$, comprising 29 focal deletions (only affecting the *IKZF1* gene and ranging from single exons to the whole gene), 19 larger deletions, and 2 cases with monosomy 7 (Table SI); the latter two types of loss are combined below as “non-focal” deletions. All except one of the 50 deletions were hemizygous; one case had a homozygous deletion of exon 1.

Of the 50 *IKZF1* deletions, 31 (62%) were detected with SNP array and 19 (38%) with MLPA analyses. The clinical features and deletion types did not differ significantly between the cases identified by SNP arrays and MLPA (Table SIII). Furthermore, the 29 cases with focal and the 21 with non-focal $\Delta IKZF1$ did not display any significant differences as regards age, gender, MRD, cytogenetic subgroups, proportion of patients with Down syndrome, risk stratification, number of patients undergoing allo SCT, or outcome (Table SIV). The cases with focal $\Delta IKZF1$ had a somewhat higher median WBC count ($29 \times 10^9/l$, range $1.6 - 496 \times 10^9/l$) compared with those with non-focal $\Delta IKZF1$ ($14 \times 10^9/l$, range $1.7 - 191 \times 10^9/l$); however, this did not reach statistical significance ($P=0.06$). The positions of the intragenic

deletions could be ascertained in 26 (90%) of the 29 cases with focal Δ IKZF1, revealing that deletions of exons 4-7 (Δ 4-7) were the most common ($N=7$; 27%). The Δ IKZF1-positive cases with or without Δ 4-7 did not appear to differ with regard to age, gender, WBC count, and frequency of events (data not shown).

Δ IKZF1 is overrepresented in the BCP-other and underrepresented in the t(12;21) groups

The frequencies of Δ IKZF1 among the cytogenetic groups were, in increasing order, 0% of cases with >67 chromosomes (0/2), 6% of t(12;21) (5/83), 7% of t(1;19) (1/14), 10% of high hyperdiploidy (HeH; 51-67 chromosomes; 12/116), 14% of iAMP21 (1/7), 25% of 11q23/*KMT2A* (1/4), 27% of dic(9;20) (3/11), 27% of BCP-other (26/95), and 50% of hypodiploidy (<45 chromosomes; 1/2).

The distributions of the cytogenetic groups hypodiploidy, HeH, dic(9;20), t(1;19), 11q23/*KMT2A*, iAMP21, and >67 chromosomes did not differ between cases with or without Δ IKZF1. In contrast, t(12;21) was significantly less common in the Δ IKZF1-positive group ($P=0.007$), whereas BCP-other was overrepresented ($P<0.001$) (Table SV).

Δ IKZF, high risk features, and outcome

The 50 Δ IKZF1-positive cases had a significantly higher median WBC count ($26 \times 10^9/l$, range of $1.6 - 492 \times 10^9/l$) than the 284 cases without Δ IKZF1 ($8.8 \times 10^9/l$, range of $0.9 - 1164 \times 10^9/l$; $P=0.009$). In addition, those with Δ IKZF1 were more frequently stratified as HR (36% vs. 14%; $P<0.001$) and were more often treated with allo SCT (8% vs. 1.4%; $P=0.02$). The presence of Δ IKZF1 was significantly associated with decreased 10-yr pEFS (60% vs. 83%; $P<0.001$) and pOS (73% vs. 89%; $P=0.001$) and increased 10-yr pRel (35% vs. 12%; $P<0.001$) (Fig 1A-C).

On the other hand, the 14 (28%) patients with Δ IKZF1 who relapsed did not differ with regard to age ($P=0.134$), WBC counts ($P=0.948$), risk group distribution ($P=0.325$), or the frequency of BCP-other ($P=0.119$) compared with the 36 cases (72%) that did not relapse. Among the latter, 32 remain in CR1, one died in CR1, and three died during induction therapy. The presence of Δ IKZF1 was not associated with increased risk of death in first complete remission (1 of 8 cases harboured a Δ IKZF1), secondary malignant neoplasm (none of 4 cases), or with central nervous system involvement (1 of 6 cases).

Δ IKZF1 and pRel in relation to risk stratification, treatment protocols, and cytogenetics

Δ IKZF1 conferred a significantly increased 10-yr pRel in the SR (36% vs. 8%; $P=0.003$) and HR (49% vs. 17%; $P=0.012$) groups (Fig 1D and E) but not in the IR group (22% vs. 12%; $P=0.237$) (Fig 1F). *IKZF1* deletions were significantly associated with increased 10-yr pRel in the NOPHO ALL-1992 (60% vs. 10%; $P<0.001$) but not in the -2000 (27% vs. 15%; $P=0.095$) and -2008 (18% vs. 4%; $P=0.073$) protocols (Fig 1G-I). In contrast, Δ IKZF1 did not significantly alter the pRel for cases with HeH (Fig S1A), t(12;21) (Fig S1B), t(1;19), dic(9;20), and iAMP21 (combined because all three changes are stratified as IR and individually rare; Fig S1C), or *KMT2A* rearrangements and hypodiploidy (combined because they are both stratified as HR and too infrequent to be investigated separately; Fig S1D).

Δ IKZF1 and pRel/pOS of BCP-other ALL

BCP-other with Δ IKZF1 had decreased pOS (58% vs. 90; $P<0.001$) and increased pRel (52% vs. 4%; $P<0.001$) (Fig 2A and B). The pRel was significantly higher for Δ IKZF1-positive BCP-other than for Δ IKZF1-negative BCP-other in all three treatment protocols [ALL-1992: 83% vs. 6%; $P<0.001$, ALL-2000: 33% vs. 4%; $P=0.010$, and ALL-2008: 37% vs. 0%; $P=0.009$].

Δ IKZF1 and MRD

MRD data were available in 33 (66%) of the 50 Δ IKZF1-positive cases, of which 14 (42%) were MRD-positive and 19 (58%) were MRD-negative at day 29. The IKZF1-positive cases more often had MRD levels $\geq 0.1\%$ than those without Δ IKZF1 (42% vs. 25%); however, this was not statistically significant ($P=0.06$). MRD-positivity did not predict relapse ($P=1.000$) in the group with Δ IKZF1; in contrast, the presence of Δ IKZF1 conferred a significantly increased 10-yr pRel in both MRD-positive (33% vs. 12%; $P=0.029$) and MRD-negative (27% vs. 7%; $P=0.018$) cases (Fig 3A and B).

Frequencies and prognostic impact of PAR1 and ERG deletions

PAR1 and ERG deletions were found in 12 (3.6%) and eight (3.3%) of the informative cases, respectively. Of the 12 patients with PAR1 deletions, four relapsed and one died, whereas of the eight ERG-deleted cases one relapsed and all remain alive.

The 10-yr pRel for cases with both *P2RY8-CRLF2* and Δ IKZF1 and for those with only Δ IKZF1 were 75% and 30%, respectively ($P=0.045$), whereas the presence of ERG deletions in Δ IKZF1-positive cases did not affect the pRel (23% vs. 26%; $P=0.832$). However, it should be emphasised that only four cases were double positive for *P2RY8-CRLF2* and Δ IKZF1 and only three were double positive for ERG and IKZF1 deletions.

Δ IKZF1 is an independent risk factor

Multivariate Cox regression analyses revealed that Δ IKZF1 was the strongest independent risk factor for relapse when age, WBC count, treatment protocol, MRD, and cytogenetic groups were included as variables in the model ($P=0.002$). The risk groups SR, IR, and HR were not used in the primary analysis because they are partly based on factors already

included. When the component factors were replaced by risk groups in the analysis, $\Delta IKZF1$ was still the strongest independent risk factor for relapse ($P < 0.001$). $\Delta IKZF1$ was also an independent risk factor for decreased EFS and OS when these were used as end-points in the model ($P = 0.002$ and $P = 0.019$, respectively) and for relapse ($P = 0.033$), EFS ($P = 0.031$), and OS ($P = 0.027$) when only patients with available MRD data were included in the analyses (Table I). When BCP-other was analysed separately, $\Delta IKZF1$ remained the strongest risk factor ($P < 0.001$). The same was also true for models including PAR1 deletion as a variable. In these models, $\Delta IKZF1$ remained the strongest risk factor ($P < 0.001$) but PAR1 deletion was also independently associated with an increased pRel ($P = 0.014$).

Discussion

In 2008, *IKZF1* deletions were for the first time associated with relapse of paediatric *BCR-ABL1*-negative BCP ALL (Yang *et al*, 2008). Since then, several studies have confirmed such an association, also in *BCR-ABL1*-positive cases (Martinelli *et al*, 2009; Mullighan *et al*, 2009; Kuiper *et al*, 2010; Waanders *et al*, 2011; Asai *et al*, 2013; Dörge *et al*, 2013; Dupuis *et al*, 2013; Öfverholm *et al*, 2013; Schwab *et al*, 2013; van der Veer *et al*, 2013, 2014; Yamashita *et al*, 2013; Olsson *et al*, 2014). More recently, however, the clinical relevance of $\Delta IKZF1$ has been questioned, either as a risk-stratifying change as such or as an independent prognostic marker when MRD data are taken into account (Chen *et al*, 2012; Palmi *et al*, 2013; Qazi *et al*, 2013; Uckun *et al*, 2013; Volejnikova *et al*, 2013). In order to address this issue further, we ascertained all 334 Swedish paediatric BCP ALL cases, diagnosed and treated according to NOPHO ALL protocols, with data on $\Delta IKZF1$. The investigated cohort did not differ from the 799 cases with unknown *IKZF1* status diagnosed during the same time period with regard to age, sex ratio, MRD, proportion of patients with Down syndrome, risk group distribution, treatment with allo SCT, and outcome; the analysed cases, however, had

somewhat higher WBC counts (Table SII). Despite the latter, we deem the present series to be representative of childhood BCP ALL in general. Support for this conclusion is the fact that 15% of the cases harboured Δ IKZF1, a frequency in accord with previous studies (Kuiper *et al*, 2010; Waanders *et al*, 2011; Chen *et al*, 2012; Caye *et al*, 2013; Dörge *et al*, 2013; Öfverholm *et al*, 2013; Schwab *et al*, 2013; van der Veer *et al*, 2013; Yamashita *et al*, 2013; Olsson *et al*, 2014).

Because most Δ IKZF1 are submicroscopic, targeted analyses are needed to identify them. Most often, SNP array or MLPA analyses are used, but more recently multiplex PCR-based methods have been developed (Mullighan *et al*, 2007, 2009; Yang *et al*, 2008; Kuiper *et al*, 2010; Schwab *et al*, 2010, 2013; Caye *et al*, 2013; Dörge *et al*, 2013; Dupuis *et al*, 2013; Meyer *et al*, 2013; Öfverholm *et al*, 2013; van der Veer *et al*, 2013, 2014; Olsson *et al*, 2014). All these three methods have their limitations. For example, deletions may well escape detection by SNP arrays and MLPA if they are present in smaller (<10% and <50%, respectively) subclones and large, *i.e.*, non-focal, deletions may be missed by multiplex PCR (Kuiper *et al*, 2007; Schwab *et al*, 2010; Li *et al*, 2011; Caye *et al*, 2013; Dupuis *et al*, 2013). Consequently, the frequencies of Δ IKZF1 may vary depending on the technique used, something that could also influence the perceived prognostic impact of Δ IKZF1. In the present study, there was no significant difference in the frequencies of Δ IKZF1 observed by SNP array (14%) and MLPA (16%) analyses, nor did the clinical features and deletion types differ between SNP- and MLPA-identified cases (Table SIII). Of the Δ IKZF1, 58% were focal and 42% were non-focal deletions. There were no significant differences in sex ratio, WBC counts, MRD, and risk group stratification between these two deletion types, and in contrast to a previous study (Dörge *et al*, 2013) that reported an association between high age (>10 years) and focal deletions, we did not find such a correlation. Additionally, and in agreement with prior findings (Dörge *et al*, 2013; Dupuis *et al*, 2013), the prognostic impact

of the deletion types did not differ significantly (Table SIV). Thus, all $\Delta IKZF1$ could be combined, irrespective of detection method and extent of the deletions, in all subsequent analyses in the present study.

$\Delta IKZF1$ influenced the prognosis negatively in the entire patient cohort, being significantly associated with decreased pEFS and pOS and increased pRel (Fig 1A-C). However, the impact varied among the different NOPHO protocols and risk groups. The pRel was significantly higher for $\Delta IKZF1$ -positive cases in the 1992 protocol (Fig. 1G) but not in the 2000 and 2008 protocols (Fig. 1H and I). This may well be due to more efficient therapy in these latter protocols. As regards risk groups, $\Delta IKZF1$ was associated with higher relapse rates in the SR and HR groups, but not in the IR group (Fig 1D-F). The reasons for this are presently unclear, but probably reflect both differences in treatment intensity and biological differences among the groups.

IKZF1 deletions were seen in all cytogenetic subgroups except the one with >67 chromosomes, with most subtypes being equally distributed among the $\Delta IKZF1$ -positive and -negative cases (Table SV). However, BCP-other was clearly overrepresented in cases with *IKZF1* deletions and there was a negative association between t(12;21) and $\Delta IKZF1$; only 6% of the cases with t(12;21) had *IKZF1* deletions. A similarly low frequency (3-5%) of $\Delta IKZF1$ in BCP ALL with t(12;21) has previously been described (Dörge *et al*, 2013; Enshaei *et al*, 2013). It has been reported that $\Delta IKZF1$ is present in approximately 20% of HeH cases and that it confers an unfavourable outcome in this subgroup (van der Veer *et al* 2013). This could, however, not be confirmed herein. We found $\Delta IKZF1$ in 10% of the HeH cases and there was no significant difference in 10-yr pRel between *IKZF1*-deleted and non-deleted HeH (Fig S1A). In fact, there was no evidence for a prognostic impact of $\Delta IKZF1$ in any of the cytogenetic subtypes (Fig S1), except for BCP-other (Fig 2A and B), in line with prior

studies (Mullighan *et al*, 2009; Dörge *et al*, 2013; Öfverholm *et al*, 2013; Schwab *et al*, 2013; Olsson *et al*, 2014).

BCP-other comprises approximately 25% of all BCP ALL cases and constitutes a substantial proportion of cases that subsequently relapse (Pui *et al*, 2011). In the present study, 95 cases, representing 28% of the entire patient cohort, were grouped as BCP-other. Of these, Δ IKZF1 was seen in 27%, comprising 52% of all Δ IKZF1-positive cases (Table SV). The presence of Δ IKZF1 was strongly associated with increased risk of relapse and decreased OS; only two of the 12 cases that relapsed in the BCP-other group did not have an *IKZF1* deletion (Fig 2). Further support for the impact of Δ IKZF1 in BCP-other is the fact that although the 10-yr pRel for Δ IKZF1-positive cases in general was only significantly increased in the NOPHO ALL-1992 protocol (Fig 1G-I), pRel for BCP-other was increased also in the 2000 and 2008 protocols. In addition, multivariate analysis showed that Δ IKZF1 was the strongest independent risk factor in this group. Hence, it is particularly important to identify Δ IKZF1 in BCP-other in order to improve risk stratification.

The presence of Δ IKZF1 was significantly associated with high WBC counts and Δ IKZF1-positive cases were more often grouped as HR, in agreement with previous studies (Den Boer *et al*, 2009; Martinelli *et al*, 2009; Mullighan *et al*, 2009; Dörge *et al*, 2013; Schwab *et al*, 2013; Yamashita *et al*, 2013, van der Veer *et al*, 2014). Despite this association between Δ IKZF1 and high risk factors, it could not explain the increased risk of relapse in the Δ IKZF1-positive group, nor could the MRD findings. In fact, more than one third of all relapses occurred in the Δ IKZF1-positive group, with the majority of these (71%) being associated with BCP-other, again strongly suggesting that BCP-other with *IKZF1* deletions comprises a specific group characterized by high relapse risk and poor outcome.

Today, MRD is considered to be the most powerful indicator for the outcome of paediatric ALL (Brisco *et al*, 1993; Cavé *et al*, 1998; van Dongen *et al*, 1998; Coustan-Smith

et al, 2002; Borowitz *et al*, 2008; Björklund *et al*, 2009). Hence, a major aim of the present study was to ascertain the impact of Δ IKZF1 in the context of MRD, an issue that has been debated (Mullighan *et al*, 2009; Waanders *et al*, 2011; Chen *et al*, 2012; Dörge *et al*, 2013; van der Veer *et al*, 2013; Volejnikova *et al*, 2013). It may be noteworthy that MRD did not seem to be a strong prognostic factor in univariate analysis of our cohort, only being borderline significant ($P=0.084$; Table I). However, it should be stressed that the majority of the cases (53%) with known MRD status were treated by the current NOPHO-2008 protocol in which MRD is risk stratifying and hence acted upon. Nonetheless, Δ IKZF1 predicted high risk of relapse in MRD-positive as well as in MRD-negative cases (Fig 3) and in multivariate analyses, with age, WBC count, MRD, treatment protocol, cytogenetic subgroups, and *IKZF1* status as variables, Δ IKZF1 was the strongest independent risk factor for relapse (Table I), as well as for inferior EFS and OS.

In some studies, the poor outcome associated with Δ IKZF1 has been suggested to be caused by an underlying genomic instability rather than by the Δ IKZF1 as such; however, this suggestion is based on MLPA data on only a limited set of genes (Palmi *et al*, 2013; Qazi & Uckun, 2013). In fact, in a recent SNP array analysis of 191 BCP ALL cases no significant difference in the frequencies of CN alterations between Δ IKZF1-positive and Δ IKZF1-negative cases was observed (Olsson *et al*, 2015). Instead, the presence of certain specific cooperative genetic changes seem to modify the prognostic impact of Δ IKZF1, such as *PAR1* and *ERG* deletions.

PAR1 and *ERG* deletions were found in 3.6% and 3.3% of the cases, respectively; frequencies on a par with previous studies (Harvey *et al*, 2010; Palmi *et al*, 2012; Yamashita *et al*, 2013; Clappier *et al*, 2014; Zaliouva *et al*, 2014). The presence of *ERG* deletions has been associated with a favourable outcome, also in the context of Δ IKZF1 (Clappier *et al*, 2014; Zaliouva *et al*, 2014). We did not detect a significant impact of *ERG* deletions on the pRel of

Δ IKZF1-positive cases; however, it should be stressed that this analysis was based on only a few patients. Interestingly, all eight patients with an *ERG* deletion are alive. In contrast, PAR1 deletions have been associated with a poor outcome (Harvey *et al*, 2010; Chen *et al*, 2012; Palmi *et al*, 2012), particularly in case double positive cases for PAR1 deletion and Δ IKZF1 (Harvey *et al*, 2010; Moorman *et al*, 2014; Olsson *et al*, 2015). The present finding of an increased pRel for double positive cases hence agrees well with previously published data.

In conclusion, analyses of *IKZF1* and PAR1 provide essential information pertaining to risk stratification in NOPHO treatment protocols, with available data indicating that it is particularly important to screen for Δ IKZF1 in cases presently grouped as BCP-other.

Acknowledgements

The authors are grateful to Dr. Erik Forestier, Umeå, Sweden, for helpful comments. This study was supported by grants from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Crafoord foundation, and the Swedish Research Council.

Author contributions

LO and IÖ performed experiments, analysed the data, and wrote the manuscript, UNN and MH provided clinical data and performed statistical analyses, VZ analysed data, JN performed experiments, HS and IG provided patient samples and data on *IKZF1* status, KP and AN analysed data, and GB and BJ designed the study, analysed the data, and wrote the manuscript. All the authors approved the final version of the manuscript.

Conflict-of-interest disclosure

The authors declare no conflict of interest.

References

- Asai, D., Imamura, T., Suenobu, S., Saito, A., Hasegawa, D., Deguchi, T., Hashii, Y., Matsumoto, K., Kawasaki, H., Hori, H., Iguchi, A., Kosaka, Y., Kato, K., Horibe, K., Yumura-Yagi, K., Hara, J. & Oda, M. (2013) *IKZF1* deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. *Cancer Medicine*, **2**, 412-419.
- Björklund, E., Matinlauri, I., Tierens, A., Axelsson, S., Forestier, E., Jacobsson, S., Ahlberg, A.J., Kauric, G., Mäntymaa, P., Osnes, L., Penttilä, T.L., Marquart, H., Savolainen, E.R., Siitonen, S., Torikka, K., Mazur, J. & Porwit, A. (2009) Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. *Journal of Pediatric Hematology/Oncology*, **31**, 406-415.
- Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N. & Camitta, B.M. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*, **111**, 5477-5485.
- Brisco, M.J., Condon, J., Hughes, E., Neoh, S.-H., Nicholson, I., Sykes, P.J., Tauro, G., Ekert, H., Water, K., Toogood, I., Seshadri, R. & Morley, A. (1993) Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. *Leukemia*, **7**, 1514-1520.
- Brüggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O.G., Asnafi, V., Baruchel, A., Bassan, R., Benoit, Y., Biondi, A., Cavé, H., Dombret, H., Fielding, A.K., Foà, R., Gökbuget, N., Goldstone, A.H., Goulden, N., Henze, G., Hoelzer, D., Janka-

- Schaub, G.E., Macintyre, E.A., Pieters, R., Rambaldi, A., Ribera, J.M., Schmiegelow, K., Spinelli, O., Stary, J., von Stackelberg, A., Kneba, M., Schrappe, M. & van Dongen, J.J. (2010) Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. *Leukemia*, **24**, 521-535.
- Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. *The New England Journal of Medicine*, **339**, 591-598.
- Caye, A., Beldjord, K., Mass-Malo, K., Drunat, S., Soulier, J., Gandemer, V., Baruchel, A., Bertrand, Y., Cavé, H. & Clappier, E. (2013) Breakpoint-specific multiplex polymerase chain reaction allows the detection of *IKZF1* intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. *Haematologica*, **98**, 597-601.
- Chen, I.M., Harvey, R.C., Mullighan, C.G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M.J., Camitta, B.M., Carroll, A.J., Devidas, M., Pullen, D.J., Payne-Turner, D., Tasian, S.K., Reshmi, S., Cottrell, C.E., Reaman, G.H., Bowman, W.P., Carroll, W.L., Loh, M.L., Winick, N.J., Hunger, S.P. & Willman, C.L. (2012) Outcome modeling with *CRLF2*, *IKZF1*, *JAK*, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **119**, 3512-3522.
- Clappier, E., Auclerc, M.F., Rapon, J., Bakkus, M., Caye, A., Khemiri, A., Giroux, C., Hernandez, L., Kabongo, E., Savola, S., Leblanc, T., Yakouben, K., Plat, G., Costa, V., Ferster, A., Girard, S., Fenneteau, O., Cayuela, J.M., Sigaux, F., Dastugue, N., Suciu, S., Benoit, Y., Bertrand, Y., Soulier, J. & Cavé, H. (2014) An intragenic *ERG* deletion is a

- marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent *IKZF1* deletions. *Leukemia*, **28**, 70-77.
- Coustan-Smith, E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. *Blood*, **100**, 52-58.
- Den Boer, M.L., van Slegtenhorst, M., De Menezes, R.X., Cheok, M.H., Buijs-Gladdines, J.G., Peters, S.T., Van Zutven, L.J., Beverloo, H.B., Van der Spek, P.J., Escherich, G., Horstmann, M.A., Janka-Schaub, G.E., Kamps, W.A., Evans, W.E. & Pieters, R. (2009) A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. *The Lancet Oncology*, **10**, 125-134.
- Dörge, P., Meissner, B., Zimmermann, M., Möricke, A., Schrauder, A., Bouquin, J.P., Schewe, D., Harbott, J., Teigler-Schlegel, A., Ratei, R., Ludwig, W.D., Koehler, R., Bartram, C.R., Schrappe, M., Stanulla, M. & Cario, G. (2013) *IKZF1* deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica*, **98**, 428-432.
- Dupuis, A., Gaub, M.P., Legrain, M., Drenou, B., Mauvieux, L., Lutz, P., Herbrecht, R., Chan, S. & Kastner, P. (2013) Biclinal and biallelic deletions occur in 20% of B-ALL cases with *IKZF1* mutations. *Leukemia*, **27**, 503-507.
- Enshaei, A., Schwab, C.J., Konn, Z.J., Mitchell, C.D., Kinsey, S.E., Wade, R., Vora, A., Harrison, C.J. & Moorman, A.V. (2013) Long-term follow-up of *ETV6-RUNX1* ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. *Leukemia*, **27**, 2256-2259.
- Frandsen, T.L., Heyman, M., Abrahamsson, J., Vettenranta, K., Åsberg, A., Vaitkeviciene, G., Pruunsild, K., Toft, N., Birgens, H., Hallböök, H., Quist-Paulsen, P., Griškevičius, L.,

- Helt, L., Hansen, B.V. & Schmiegelow, K. (2014) Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. *European Journal of Cancer*, **50**, 251-259.
- Georgopoulos, K., Moore, D.D. & Derfler, B. (1992) Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. *Science*, **258**, 808-812.
- Harvey, R.C., Mullighan, C.G., Chen, I.M., Wharton, W., Mikhail, F.M., Carroll, A.J., Kang, H., Liu, W., Dobbin, K.K., Smith, M.A., Carroll, W.L., Devidas, M., Bowman, W.P., Camitta, B.M., Reaman, G.H., Hunger, S.P., Downing, J.R. & Willman, C.L. (2010) Rearrangement of *CRLF2* is associated with mutation of *JAK* kinases, alteration of *IKZF1*, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*, **115**, 5312-5321.
- Kuiper, R.P., Schoenmakers, E.F., van Reijmersdal, S.V., Hehir-Kwa, J.Y., van Kessel, A.G., van Leeuwen, F.N. & Hoogerbrugge, P.M. (2007) High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. *Leukemia*, **21**, 1258-1266.
- Kuiper, R.P., Waanders, E., van der Velden, V.H.J., van Reijmersdal, S.V., Venkatachalam, R., Scheijen, B., Sonneveld, E., van Dongen, J.J.M., Veerman, A.J.P., van Leeuwen, F.N., van Kessel, A.G. & Hoogerbrugge, P.M. (2010) *IKZF1* deletions predict relapse in uniformly treated pediatric precursor B-ALL. *Leukemia*, **24**, 1258-1264.
- Li, A., Liu, Z., Lezon-Geyda, K., Sarkar, S., Lannin, D., Schulz, V., Krop, I., Winer, E., Harris, L. & Tuck, D. (2011) GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. *Nucleic Acids Research*, **39**, 4928-4941.
- Martinelli, G., Iacobucci, I., Storlazzi, C.T., Vignetti, M., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Papayannidis, C., Paolini, S., Elia, L., Fazi, P.,

- Meloni, G., Amadori, S., Saglio, G., Pane, F., Baccarani, M. & Foà, R. (2009) *IKZF1* (Ikaros) deletions in *BCR-ABL1*-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *Journal of Clinical Oncology*, **27**, 5202-5207.
- Meyer, C., Zur Stadt, U., Escherich, G., Hofmann, J., Binato, R., Barbosa Tda, C., Emerenciano, M., Pombo-de-Oliveira, M.S., Horstmann, M. & Marschalek, R. (2013) Refinement of *IKZF1* recombination hotspots in pediatric BCP-ALL patients. *American Journal of Blood Research*, **3**, 165-173.
- Moorman, A.V., Enshaei, A., Schwab, C., Wade, R., Chilton, L., Elliott, A., Richardson, S., Hancock, J., Kinsey, S.E., Mitchell, C.D., Goulden, N., Vora, A. & Harrison, C.J. (2014) A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. *Blood*. **28**, 124, 1434-1444.
- Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature*, **446**, 758-764.
- Mullighan, C.G., Su, X., Zhang, J., Radtke, I., Phillips, L.A., Miller, C.B., Ma, J., Liu, W., Cheng, C., Schulman, B.A., Harvey, R.C., Chen, I.M., Clifford, R.J., Carroll, W.L., Reaman, G., Bowman, W.P., Devidas, M., Gerhard, D.S., Yang, W., Relling, M.V., Shurtleff, S.A., Campana, D., Borowitz, M.J., Pui, C.H., Smith, M., Hunger, S.P., Willman, C.L. & Downing, J.R. (2009) Deletion of *IKZF1* and prognosis in acute lymphoblastic leukemia. *The New England Journal of Medicine*, **360**, 470-480.
- Öfverholm, I., Tran, A.N., Heyman, M., Zachariadis, V., Nordenskjöld, M., Nordgren, A. & Barbany, G. (2013) Impact of *IKZF1* deletions and *PAX5* amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. *Leukemia*, **27**, 1936-1939.

- Olsson, L., Castor, A., Behrendtz, M., Biloglav, A., Forestier, E., Paulsson, K. & Johansson, B. (2014) Deletions of *IKZF1* and *SPRED1* are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. *Leukemia*, **28**, 302-310.
- Olsson, L. & Johansson, B. (2015) Ikaros and leukaemia. *British Journal of Haematology* (in press).
- Olsson, L., Albitar, F., Castor, A., Behrendtz, M., Biloglav, A., Paulsson, K. & Johansson, B. (2015) Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of *IKZF1*. *Genes, Chromosomes & Cancer*, **54**, 315-325.
- Palmi, C., Vendramini, E., Silvestri, D., Longinotti, G., Frison, D., Cario, G., Shochat, C., Stanulla, M., Rossi, V., Di Meglio, A.M., Villa, T., Giarin, E., Fazio, G., Leszl, A., Schrappe, M., Basso, G., Biondi, A., Izraeli, S., Conter, V., Valsecchi, M.G., Cazzaniga, G. & Te Kronnie, G. (2012) Poor prognosis for *P2RY8-CRLF2* fusion but not for *CRLF2* over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. *Leukemia*, **26**, 2245-2253.
- Palmi, C., Valsecchi, M.G., Longinotti, G., Silvestri, D., Carrino, V., Conter, V., Basso, G., Biondi, A., Kronnie, G.T. & Cazzaniga, G. (2013) What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? *Haematologica*, **98**, 1226-1231.
- Pui, C.H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. *Journal of Clinical Oncology*, **29**, 551-565.

- Qazi, S. & Uckun, F.M. (2013) Incidence and biological significance of *IKZF1*/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia. *Haematologica*, **98**, e151-152.
- Qazi, S., Ma, H. & Uckun, F.M. (2013) Absence of genomic Ikaros/*IKZF1* deletions in pediatric B-precursor acute lymphoblastic leukemia. *International Journal of Molecular Medical Science*, **3**, 72-82.
- Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Söderhäll, S. & Taskinen, M. (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukaemia. *Leukemia*, **24**, 345-354.
- Schwab, C.J., Jones, L.R., Morrison, H., Ryan, S.L., Yigittop, H., Schouten, J.P. & Harrison, C.J. (2010) Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. *Genes, Chromosomes & Cancer*, **49**, 1104-1113.
- Schwab, C.J., Chilton, L., Morrison, H., Jones, L., Al-Shehhi, H., Erhorn, A., Russell, L.J., Moorman, A.V. & Harrison, C.J. (2013) Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. *Haematologica*, **98**, 1081-1088.
- Toft, N., Birgens, H., Abrahamsson, J., Bernell, P., Griškevičius, L., Hallböök, H., Heyman, M., Holm, M.S., Hulegårdh, E., Klausen, T.W., Marquart, H.V., Jónsson, O.G., Nielsen, O.J., Quist-Paulsen, P., Taskinen, M., Vaitkeviciene, G., Vettenranta, K., Åsberg, A. & Schmiegelow, K. (2013) Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. *European Journal of Haematology*, **90**, 404-412.
- Uckun, F.M., Ma, H., Ishkhanian, R., Arellano, M., Shahidzadeh, A., Termuhlen, A., Gaynon, P.S. & Qazi, S. (2013) Constitutive function of the Ikaros transcription factor in primary

- leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. *PLoS One*, **8**, e80732.
- van der Veer, A., Waanders, E., Pieters, R., Willemse, M.E., Van Reijmersdal, S.V., Russell, L.J., Harrison, C.J., Evans, W.E., van der Velden, V.H.J., Hoogerbrugge, P.M., Van Leeuwen, F., Escherich, G., Horstmann, M.A., Mohammadi Khankahdani, L., Rizopoulos, D., De Groot-Kruseman, H.A., Sonneveld, E., Kuiper, R.P. & Den Boer, M.L. (2013) Independent prognostic value of *BCR-ABL1-like* signature and *IKZF1* deletion, but not high *CRLF2* expression, in children with B-cell precursor ALL. *Blood*, **122**, 2622-2629.
- van der Veer, A., Zaliouva, M., Mottadelli, F., De Lorenzo, P., Te Kronnie, G., Harrison, C.J., Cavé, H., Trka, J., Saha, V., Schrappe, M., Pieters, R., Biondi, A., Valsecchi, M.G., Stanulla, M., den Boer, M.L. & Cazzaniga, G. (2014) *IKZF1* status as a prognostic feature in *BCR-ABL1*-positive childhood ALL. *Blood*, **123**, 1691-1698.
- van Dongen, J.J.M., Seriu, T., Panzer-Grümayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C.J., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. *The Lancet*, **352**, 1731-1738.
- Volejnikova, J., Mejstrikova, E., Dörge, P., Meissner, B., Zimmermannova, O., Svojgr, K., Stanulla, M., Cario, G., Schrappe, M., Stary, J., Hrusak, O., Trka, J. & Fronkova, E. (2013) Ikaros (*IKZF1*) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood *BCR/ABL*-negative acute lymphoblastic leukemia. *Pediatric Blood & Cancer*, **60**, 420-427.
- Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C. & Richards, S. (2013) Treatment reduction for children and young adults with low-risk acute

- lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. *The Lancet Oncology*, **14**, 199-209.
- Waanders, E., van der Velden, V.H.J., van der Schoot, C.E., van Leeuwen, F.N., van Reijmersdal, S.V., de Haas, V., Veerman, A.J., van Kessel, A.G., Hoogerbrugge, P.M., Kuiper, R.P. & van Dongen, J.J.M. (2011) Integrated use of minimal residual disease classification and *IKZF1* alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. *Leukemia*, **25**, 254-258.
- Yamaji, K., Okamoto, T., Yokota, S., Watanabe, A., Horikoshi, Y., Asami, K., Kikuta, A., Hyakuna, N., Saikawa, Y., Ueyama, J., Watanabe, T., Okada, M., Taga, T., Kanegane, H., Kogawa, K., Chin, M., Iwai, A., Matsushita, T., Shimomura, Y., Hori, T. & Tsurusawa, M. (2010) Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. *Pediatric Blood & Cancer*, **55**, 1287-1295.
- Yamashita, Y., Shimada, A., Yamada, T., Yamaji, K., Hori, T., Tsurusawa, M., Watanabe, A., Kikuta, A., Asami, K., Saito, A.M. & Horibe, K. (2013) *IKZF1* and *CRLF2* gene alterations correlate with poor prognosis in Japanese *BCR-ABL1*-negative high-risk B-cell precursor acute lymphoblastic leukemia. *Pediatric Blood & Cancer*, **60**, 1587-1592.
- Yang, J.J., Bhojwani, D., Yang, W., Cai, X., Stocco, G., Crews, K., Wang, J., Morrison, D., Devidas, M., Hunger, S.P., Willman, C.L., Raetz, E.A., Pui, C.H., Evans, W.E., Relling, M.V. & Carroll, W.L. (2008) Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. *Blood*, **112**, 4178-4183.
- Zaliova, M., Zimmermannova, O., Dörge, P., Eckert, C., Möricke, A., Zimmermann, M., Stuchly, J., Teigler-Schlegel, A., Meissner, B., Koehler, R., Bartram, C.R., Karawajew, L., Rhein, P., Zuna, J., Schrappe, M., Cario, G. & Stanulla, M. (2014) *ERG* deletion is

associated with CD2 and attenuates the negative impact of *IKZF1* deletion in childhood acute lymphoblastic leukemia. *Leukemia*, **28**, 182-185.

Figure legends

Fig 1. Kaplan-Meier estimates of pEFS, pOS, and pRel of BCP ALL cases with and without *IKZF1* deletions in the total patient cohort (A-C) and of pRel in relation to risk groups (D-F) and treatment protocols (G-I). In each plot, the curve representing cases with Δ IKZF1 is denoted in blue and the one representing non-deleted cases in green. In the entire cohort, the 10-yr pEFS (A) was 0.60 (standard error 0.08) for Δ IKZF1-positive and 0.83 (0.03) for Δ IKZF1-negative cases, the 10-yr pOS (B) 0.73 (0.07) and 0.89 (0.03), and the 10-yr pRel (C) 0.35 (0.08) and 0.12 (0.02). In relation to risk group, the 10-yr pRel for SR (D) was 0.36 (0.15) for Δ IKZF1-positive and 0.08 (0.04) or Δ IKZF1-negative cases, for HR (E) 0.49 (0.14) and 0.17 (0.06), and for IR (F) 0.22 (0.11) and 0.12 (0.03). In relation to treatment protocol, the 10-yr pRel for NOPHO ALL-1992 (G) was 0.60 (0.16) for Δ IKZF1-positive and 0.10 (0.04) for Δ IKZF1-negative cases, for NOPHO ALL-2000 (H) 0.27 (0.10) and 0.15 (0.04), and for NOPHO ALL-2008 (I) 0.18 (0.12) and 0.04 (0.02).

Fig 2. Kaplan-Meier estimates of pOS and pRel in the BCP-other group. In each plot, the curve representing cases with Δ IKZF1 is denoted in blue and the one representing non-deleted cases in green. (A) The 10-yr pOS was 0.58 (0.10) for Δ IKZF1-positive and 0.90 (0.06) for Δ IKZF1-negative cases. (B) The 10-yr pRel was 0.52 (0.12) for Δ IKZF1-positive and 0.04 (0.03) for Δ IKZF1-negative cases.

Fig 3. Kaplan-Meier estimates of pRel in the 132 MRD-positive and 87 MRD-negative BCP ALL cases. In each plot, the curve representing cases with Δ IKZF1 is denoted in blue and the one representing non-deleted cases in green. (A) In the MRD-positive group, the 10-yr pRel was 0.33 (0.12) for Δ IKZF1-positive and 0.12 (0.04) for Δ IKZF1-negative cases. (B) In the

MRD-negative group, the 10-yr pRel was 0.27 (0.17) for Δ IKZF1-positive and 0.07 (0.03) for Δ IKZF1-negative cases.

Supporting information

Additional supporting information is found in the online version of this article:

Table SI. Clinical and genetic features of the 334 BCP ALL cases with known *IKZF1* status.

Table SII. Comparisons between BCP ALLs with and without known *IKZF1* status.

Table SIII. Comparisons between Δ IKZF1-positive cases detected with SNP array and MLPA analyses.

Table SIV. Comparisons between focal and non-focal Δ IKZF1-positive cases.

Table SV. Distribution of cytogenetic subgroups in the *IKZF1* deleted and non-deleted cases.

Fig S1. Kaplan-Meier estimates of pRel of BCP ALL cases positive and negative for *IKZF1* deletions in relation to cytogenetic features.

Table I. Multivariate Cox regression analyses of pRel.*

Risk factor	N	Univariate RR (95% CI)	Multivariate RR (95% CI)	P-value [†] univ/multiv
Age (years)				
10-17	37	2.13 (0.83-5.49)	1.79 (0.58-5.47)	0.118/0.310
1-9	181	1.0		
WBC (x 10 ⁹ /l)				
≥50	38	2.92 (1.18-7.26)	2.76 (1.026-7.44)	0.021/0.044
<50	180	1.0		
MRD				
≥0.1%	60	2.14 (0.90-5.09)	1.52 (0.60-3.85)	0.084/0.383
<0.1%	158	1.0		
Cytogenetic group [‡]				
Group 1	133	1.0		
Group 2	19	1.18 (0.26-5.32)	0.50 (0.10-2.60)	0.830/0.407
Group 3	6	8.92 (1.90-41.83)	2.70 (0.43-16.94)	0.006/0.289
Group 4	60	1.13 (0.42-3.05)	0.62 (0.20-1.93)	0.812/0.408
Treatment protocol				
ALL-2000	103	1.0		
ALL-2008	115	0.48 (0.17-1.35)	0.47 (0.16-1.38)	0.165/0.171
<i>IKZF1</i> deletion				
Yes	32	3.85 (1.60-9.29)	3.06 (1.09-8.54)	0.003/0.033
No	186	1.0		

CI, confidence interval; MRD, minimal residual disease; N, number; pRel, cumulative incidence of relapse; RR, relative risk; univ/multiv, univariate/multivariate; WBC, white blood cell count.

*Based on 218 patients with available MRD data (one MRD-positive case was censored), including 21 that relapsed and 32 that had *IKZF1* deletions.

[†]Significant *P*-values are indicated in bold type.

[‡]Group 1: HeH, t(12;21), and >67 chromosomes; group 2: t(1;19), dic(9;20), and iAMP21; group 3: hypodiploidy and *KMT2A* rearrangements; and group 4: BCP-other.

Fig 1A

Fig 1B

Fig 1C

Fig 1D

Fig 1E

Fig 1F

Fig 1G

Fig 1H

Fig 1I

Fig 2A

Fig 2B

Fig 3A

Fig 3B